drugset / Trial / NCT04906746
Ruxolitinib for Cancer Cachexia
NaSingle-groupOpen-labelTreatment
Summary
To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
Timeline
- Start
- 2022-02-23
- Primary completion
- 2024-09-27
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |